Anaplastic lymphoma kinase and its signalling molecules
as novel targets in lymphoma therapy
.

 

[<<Previous]

[ <<To the list of latest publications ]

[ Next>> ]


Expert Opin Ther Targets, 9: 515-532, 2005.

Coluccia, A. M., Gunby, R. H., Tartari, C. J., Scapozza, L.,
Gambacorti-Passerini, C., and Passoni, L.

A crucial issue in the development of molecularly-targeted anticancer therapies is the identification of appropriate molecules whose targeting would result in tumour regression with a minimal level of systemic toxicity. Anaplastic lymphoma kinase (ALK) is a transmembrane receptor tyrosine kinase, normally expressed at low levels in the nervous system. As a consequence of chromosomal translocations involving the alk gene (2p23), ALK is also aberrantly expressed and constitutively activated in ~ 60% of CD30+ anaplastic large cell lymphomas (ALCLs). Due to the selective overexpression of ALK in tumour cells, its direct involvement in the process of malignant transformation and its frequent expression in ALCL patients, the authors recognise ALK as a suitable candidate for the development of molecularly targeted strategies for the therapeutic treatment of ALK-positive lymphomas. Strategies targeting ALK directly or indirectly via the inhibition of the protein networks responsible for ALK oncogenic signalling are discussed.

Full article available at
http://www.ashley-pub.com >>
 

[<<Previous]

[ <<To the list of latest publications ]

[ Next>> ]